This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 20 Sept 2023
5 min

Overview of the safety and efficacy data from ICARIA-MM Trial

Author: Sanofi

Presented by Dr Ramasamy

  

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Prescribing Information for SARCLISA®▼ (isatuximab) can be found via the Product Card at the bottom of the page.

In this video, you'll learn about

The phase 3 ICARIA-MM study of an anti-CD38 monoclonal antibody triplet regimen in relapsed and refractory multiple myeloma(RRMM) presented by Dr Ramasamy.

SARCLISA® + Pd demonstrated a 40% risk reduction in progression or death vs Pd (11.53 vs 6.47 months [absolute change 5 months]; HR 0.596, 95% CI: 0.44, 0.81; p=0.001).1

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA® patient information.

1/3

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA® patient information.

Get in touch with the Oncology Team

Relapsed Refractory Multiple Myeloma Product

 

MAT-XU-2202578 (v3.0)
Date of preparation: December 2023

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

References

  1. Attal M, et al. Lancet. 2019;394:2096–107.

MAT-XU-2202565 (v2.0) Date of Preparation: December 2023